CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,310,155)	$ (20,810,973)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,924,303	2,977,603
Non-cash lease expense	(2,970)	5,008
Share-based payments for services	587,285	778,571
Equity based compensation	1,470,491	3,544,569
Common stock contributed to 401(k) plan	164,510	162,969
Shares issued for settlement of clinical development costs	350,885	0
Loss on patent impairment	13,312	0
(Increase)/decrease in assets:
Prepaid expenses	(13,874)	(15,708)
Supplies used for R&D and manufacturing	622,831	(304,097)
Increase (Decrease) in Deposits	(4,000)	(46,884)
Increase/(decrease) in liabilities:
Accounts payable	2,444	(592,370)
Accrued expenses	(60,490)	167,568
Due to employees	806,214	139,243
Net cash used in operating activities	(12,449,214)	(13,994,501)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(32,954)	(75,122)
Expenditures for patent costs	0	(13,211)
Net cash used in investing activities	(32,954)	(88,333)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and pre-funded warrants	12,560,300	12,730,000
Payments of stock issuance costs	(1,531,832)	(1,173,577)
Proceeds from the purchase of stock by officers and directors	0	80,620
Proceeds from notes payable	350,000	0
Payments of notes payable	(350,000)	0
Payments on obligations under finance leases	(1,491,617)	(1,315,291)
Net cash provided by financing activities	9,536,851	10,321,752
NET DECREASE IN CASH AND CASH EQUIVALENTS	(2,945,317)	(3,761,083)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	4,738,173	4,145,735
CASH AND CASH EQUIVALENTS, END OF PERIOD	1,792,856	384,652
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Finance lease obligation included in accounts payable	838	1,296
Assets purchased under finance leases	0	20,797
Obligations paid with issuance of common stock	583,447	738,832
Accrued consulting services to be paid with common stock	0	110,000
Financing costs included in current liabilities	168,740	91,975
Property and equipment purchases included in current liabilities	0	2,770
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:
Cash paid for interest	$ 592,644	$ 706,517